title: Optimizing the efficiency and quality of sipuleucel-T delivery in an academic institution.
abstract: BACKGROUND
  Sipuleucel-T, an autologous cellular immunotherapy, is approved for the treatment of certain patients with metastatic castration-resistant prostate cancer (mCRPC). Sipuleucel-T is the first personalized treatment for prostate cancer to be manufactured using the immune system of each individual patient. Patient preparation and compliance are critical because patients undergo serial leukapheresis and reinfusion procedures within a relatively short time period, which may result in transient reactions.
  
  
  OBJECTIVE
  The study aims to identify patients best suited for sipuleucel-T treatment, provide an overview of treatment, and encourage infusion sites to consider a primary contact model for the efficient coordination of care.
  
  
  METHODS
  Treatment experiences were evaluated from 124 patients with mCRPC who received sipuleucel-T from January 2010 to August 2013 according to current best practices. Feedback was collected from reflective interdisciplinary discussion within the sipuleucel-T delivery team (nurses, advanced practice providers, urologists, and medical oncologists).
  
  
  RESULTS
  Early patient identification and education on treatment rationale, delivery, and expectations help ensure a successful sipuleucel-T treatment experience. A multidisciplinary coordinated-care process can facilitate proficient sipuleucel-T delivery, and the selection of a primary contact for care coordination offers benefits, such as clear and efficient education.
authors.affiliation: Duke Cancer Institute in Durham, NC.
authors.forename: Kristen
authors.initials: K
authors.lastname: Davis
authors.affiliation: Duke Cancer Institute in Durham, NC.
authors.forename: Sarah
authors.initials: S
authors.lastname: Wood
authors.affiliation: Duke Raleigh Hospital in Raleigh, NC.
authors.forename: Emily
authors.initials: E
authors.lastname: Dill
authors.affiliation: Duke Raleigh Hospital and the Duke Cancer Institute.
authors.forename: Yuri
authors.initials: Y
authors.lastname: Fesko
authors.affiliation: Wake Forest Baptist Health in Winston-Salem, NC.
authors.forename: Rhonda L
authors.initials: RL
authors.lastname: Bitting
authors.affiliation: Duke Cancer Institute.
authors.forename: Michael R
authors.initials: MR
authors.lastname: Harrison
authors.affiliation: Duke Cancer Institute.
authors.forename: Andrew J
authors.initials: AJ
authors.lastname: Armstrong
authors.affiliation: Duke Cancer Institute.
authors.forename: Judd W
authors.initials: JW
authors.lastname: Moul
authors.affiliation: Duke Cancer Institute.
authors.forename: Daniel J
authors.initials: DJ
authors.lastname: George
mesh_terms: D000046:Academic Medical Centers; D019496:Cancer Vaccines / Q000627:therapeutic use*; D003266:Continuity of Patient Care; D006801:Humans; D007167:Immunotherapy / Q000379:methods*; D007937:Leukapheresis; D008297:Male; D009657:North Carolina; D010353:Patient Education as Topic; D018579:Patient Selection; D064129:Prostatic Neoplasms, Castration-Resistant / Q000276:immunology* / Q000628:therapy*; D014020:Tissue Extracts / Q000627:therapeutic use*
chemical_list: D019496:Cancer Vaccines; D014020:Tissue Extracts; C511774:sipuleucel-T
keywords: best practice; castration-resistant prostate cancer; immunotherapy; metastatic; sipuleucel-T